ANNX Stock Price
Annexon, Inc.
ANNX stock price is $3.75 (+9.94% on the day), giving Annexon, Inc. a market cap of $646.46M. Below are the price chart, the MarketXLS Rank, the company profile and the latest news.
ANNX Stock Overview
- Price
- $3.75
- Previous close
- $3.41
- Open
- $3.65
- Market cap
- $646.46M
- P/E ratio
- -3.1
- 52-week range
- $2.54 - $7.18
- 1-year price target
- $15.63
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NGS
- MarketXLS Rank
- 39
About Annexon, Inc.
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company's lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | ANNX | $3.75 | +9.9% | 2.55M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |